They also showed that the combined therapy of HAC (anti-human PD-L1 small protein) and anti-CD47 enhanced anti-tumor efficacy and survival rate in a human DLD/GFP+ colon cancer xenograft mouse model with NSG mice. The gene discussed is CD47; the disease is neoplasm.